Enterococcus faecalis from newborn babies regulate endogenous PPARγ activity and IL-10 levels in colonic epithelial cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 6, 2008, Pages 1943-1948

  Are, Alexandra ^a   Aronsson, Linda ^a   Wang, Shugui ^b   Greicius, Gediminas ^a   Yuan, Kun Lee ^b   Gustafsson, Jan Åke ^a   Pettersson, Sven ^a,c   Arulampalam, Velmurugesan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

Microbe host interaction; Nuclear receptors; Transcription

Indexed keywords

ADIPOPHILIN; CIGLITAZONE; INTERLEUKIN 10; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN FASTING INDUCED ADIPOSE FACTOR; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; COLON MUCOSA; COMPLEX FORMATION; CONTROLLED STUDY; DNA BINDING; ENTEROCOCCUS FAECALIS; EPITHELIUM CELL; GENE INTERACTION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; INNATE IMMUNITY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

COLON; DNA; ENTEROCOCCUS FAECALIS; GENE EXPRESSION; HT29 CELLS; HUMANS; INFANT, NEWBORN; INTERLEUKIN-10; INTESTINAL MUCOSA; LIGANDS; MEMBRANE PROTEINS; PHOSPHORYLATION; PPAR GAMMA; PROTEIN BINDING;

ENTEROCOCCUS FAECALIS;

EID: 41149098050     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0711734105     Document Type: Article

References (44)

1. Chinetti-Gbaguidi G, Fruchart JC, Staels B (2005) Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: New approaches to therapy. Curr Opin Pharmacol 5:177-183.
2. Lehmann JM, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
3. Fajas L, et al. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779-18789.
4. Koeffler HP (2003) Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9:1-9.
5. Sarraf P, et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046-1052.
6. Blaut M, Clavel T (2007) Metabolic diversity of the intestinal microbiota: Implications for health and disease. J Nutr 137:751S-755S.
7. Sansonetti PJ (2004) War and peace at mucosal surfaces. Nature Rev 4:953-964.
8. Bookout AL, et al. (2006) Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126:789-799.
9. Coste A, et al. (2007) LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proc Natl Acad Sci USA 104:13098-13103.
10. Arulampalam V, Greicius G, Pettersson S (2006) The long and winding road to gut homeostasis. Curr Opin Gastroenterol 22:349-353.
11. Xu J, Gordon JI (2003) Inaugural Article: Honor thy symbionts. Proc Natl Acad Sci USA 100:10452-10459.
12. Kelly D, et al. (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nature Immunol 5:104-112.
13. Adams M, et al. (1997) Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272:5128-5132.
14. Hu E, Kim JB, Sarraf P, Spiegelman BM (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274:2100-2103.
15. Chana RS, Lewington AJ, Brunskill NJ (2004) Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: Thiazolidinediones are partial PPAR gamma agonists. Kidney Int 65:2081-2090.
16. Zhang B, et al. (1996) Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 271:31771-31774.
17. Floyd ZE, Stephens JM (2002) Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem 277:4062-4068.
18. Hauser S, et al. (2000) Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 275:18527-18533.
19. Ge H, et al. (2005) Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 46:1484-1490.
20. Mandard S, et al. (2004) The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 279:34411-34420.
21. Hooper LV, Falk PG, Gordon JI (2000) Analyzing the molecular foundations of commensalism in the mouse intestine. Curr Opin Microbiol 3:79-85.
22. Burns KA, Vanden Heuvel JP (2007) Modulation of PPAR activity via phosphorylation. Biochimica et Biophysica Acta 1771:952-960.
23. Decker T, Kovarik P (2000) Serine phosphorylation of STATs. Oncogene 19:2628-2637.
24. Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2:599-609.
25. Iankova I, et al. (2006) Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol Endocrinol 20:1494-1505.
26. Abreu MT, Fukata M, Arditi M (2005) TLR signaling in the gut in health and disease. J Immunol 174:4453-4460.
27. Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123:993-999.
28. Dubuquoy L, et al. (2003) Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124:1265-1276.
29. Adachi M, et al. (2006) Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55:1104-1113.
30. Dubuquoy L, et al. (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341-1349.
31. Lytle C, et al. (2005) The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 11:231-243.
32. Garcia-Galaz A, Perez-Morales R, Diaz-Cinco M, Acedo-Felix E (2004) Resistance of Enterococcus strains isolated from pigs to gastrointestinal tract and antagonistic effect against Escherichia coli K88. Rev Latinoam Microbiol 46:5-11.
33. Lupp C, et al. (2007) Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae. Cell Host Microbe 2:119 -129.
34. Bassaganya-Riera J, et al. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127:777-791.
35. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244-251.
36. Szatmari I, et al. (2007) PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 110:3271-3280.
37. Colgan SP, Hershberg RM, Furuta GT, Blumberg RS (1999) Ligation of intestinal epithelial CD1d induces bioactive IL-10: Critical role of the cytoplasmic tail in autocrine signaling. Proc Natl Acad Sci USA 96:13938-13943.
38. Szatmari I, et al. (2006) PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med 203:2351-2362.
39. Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: Human gut microbes associated with obesity. Nature 444:1022-1023.
40. Turnbaugh PJ, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027-1031.
41. Arbibe L, et al. (2007) An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nature Immunol 8:47-56.
42. Finlay BB, McFadden G (2006) Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens. Cell 124:767-782.
43. Juge-Aubry C, et al. (1997) DNA binding properties of peroxisome proliferatoractivated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J Biol Chem 272:25252-25259.
44. Schreiber E, Matthias P, Muller MM, Schaffner W (1989) Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells. Nucleic Acids Res 17:6419.